CORT — Corcept Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $12.26bn
- $11.94bn
- $761.41m
Corcept Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Corcept Therapeutics Q1 EPS USD 0.17 Vs. IBES Estimate USD 0.14
Corcept Therapeutics Inc expected to post earnings of 14 cents a share - Earnings Preview
Live Markets: Gauging the seat grab in index musical chairs
Brief: Diabetes Care Publishes Results From Prevalence Phase Of Corcept’S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
Brief: Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab
U.S. RESEARCH ROUNDUP-AIG, Corcept Therapeutics, Dow
Corcept hits record high as ovarian cancer drug succeeds late-stage trial
Corcept soars as ovarian cancer drug succeeds late-stage trial
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump (updated)
Corcept's ovarian cancer combination drug meets main goal in late-stage study
Brief: Corcept Therapeutics launches study on link between high cortisol and resistant hypertension
Brief: FDA Files Corcept’s New Drug Application For Relacorilant As Treatment For Patients With Hypercortisolism
Corcept Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Corcept Therapeutics Q4 EPS USD 0.26 Vs. IBES Estimate USD 0.43
Corcept Therapeutics Inc expected to post earnings of 43 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Estée Lauder, IBM, Meta
Brief: Corcept Submits New Drug Application For Relacorilant As A Treatment For Patients With Hypercortisolism
Corcept Therapeutics' ALS drug fails in mid-stage trial (updated)